Fund shareholders of Aldeyra Therapeutics Inc
ISIN US01438T1060 · United States · LEI 529900HGKY864E4Y9014
- Fund shareholders
- 111
- Of which ETFs
- 17 94 other funds
- Value held
- ≈ 17.6M $ 17.4M $ · 220.4K €
- Share of capital
- 13.2 % of 60.3M shares on Aug 4, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Russell 2000 2x Strategy Fund Rydex Dynamic Funds | 277 | 468.1 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| PROFUND VP ULTRA SMALL CAP ProFunds | 181 | 305.9 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| PROFUND VP SMALL CAP ProFunds | 137 | 231.5 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Russell 2000 Fund Rydex Series Funds | 127 | 214.6 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SMALL-CAP PROFUND ProFunds | 99 | 150.5 $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 76 | 128.4 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Columbia Research Enhanced Small Cap ETF Columbia ETF Trust I | 57 | 96.3 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ProShares Hedge Replication ETF ProShares Trust | 56 | 305.8 $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 16 | 87.4 $ | 0.01 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 15 | 25.4 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 220.4K € | 0.27 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Invesco NASDAQ Future Gen 200 ETF Invesco Exchange-Traded Fund Trust II | 0.47 % | as of Feb 28, 2026 ↗ |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 0.27 % | as of Dec 31, 2025 ↗ |
| NORTH SQUARE KENNEDY MICROCAP FUND Exchange Place Advisors Trust | 0.25 % | as of Feb 28, 2026 ↗ |
| AlphaCentric Life Sciences and Healthcare Fund MUTUAL FUND SERIES TRUST | 0.16 % | as of Mar 31, 2026 ↗ |
| Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF Goldman Sachs ETF Trust | 0.05 % | as of Feb 28, 2026 ↗ |
| PACE Small/Medium Co Growth Equity Investments PACE SELECT ADVISORS TRUST | 0.03 % | as of Apr 30, 2026 ↗ |
| iShares Micro-Cap ETF iShares Trust | 0.02 % | as of Mar 31, 2026 ↗ |
| VANGUARD RUSSELL 2000 GROWTH INDEX FUND VANGUARD SCOTTSDALE FUNDS | 0.02 % | as of Feb 28, 2026 ↗ |
| Multi-Manager Small Cap Equity Strategies Fund COLUMBIA FUNDS SERIES TRUST I | 0.01 % | as of Feb 28, 2026 ↗ |
| VANGUARD U.S. MOMENTUM FACTOR ETF VANGUARD WELLINGTON FUND | 0.01 % | as of Feb 28, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 110 | -7 | 7,955,746 | -1.8 % |
| 2026Q1 | 117 | +1 | 8,100,843 | +0.5 % |
| 2025Q4 | 116 | +4 | 8,062,616 | -6.4 % |
| 2025Q3 | 112 | -10 | 8,617,169 | -0.3 % |
| 2025Q2 | 122 | -2 | 8,641,680 | -12.3 % |
| 2025Q1 | 124 | -2 | 9,855,347 | +5.6 % |
| 2024Q4 | 126 | +18 | 9,329,778 | +5.4 % |
| 2024Q3 | 108 | -10 | 8,850,640 | +3.2 % |
| 2024Q2 | 118 | -2 | 8,578,690 | +3.8 % |
| 2024Q1 | 120 | -13 | 8,264,620 | -21.9 % |
| 2023Q4 | 133 | 10,579,906 |
Institutional managers
119 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| Knoll Capital Management, LLC | 5,475,516 | 9.3M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 3,763,887 | 6.4M $ | as of Mar 31, 2026 |
| AQR CAPITAL MANAGEMENT LLC | 2,829,875 | 4.8M $ | as of Mar 31, 2026 |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 2,152,315 | 3.6M $ | as of Mar 31, 2026 |
| 683 Capital Management, LLC | 1,500,000 | 2.5M $ | as of Mar 31, 2026 |
| D. E. Shaw & Co., Inc. | 1,403,990 | 2.4M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 1,251,652 | 2.1M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 1,124,710 | 1.9M $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 995,243 | 1.7M $ | as of Mar 31, 2026 |
| JANE STREET GROUP, LLC | 968,891 | 1.6M $ | as of Mar 31, 2026 |
| ARDSLEY ADVISORY PARTNERS LP | 950,000 | 1.6M $ | as of Mar 31, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | 863,187 | 1.5M $ | as of Mar 31, 2026 |
| ACADIAN ASSET MANAGEMENT LLC | 858,288 | 1.4K $ | as of Mar 31, 2026 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 796,816 | 1.3M $ | as of Mar 31, 2026 |
| Propel Bio Management, LLC | 730,606 | 1.2M $ | as of Mar 31, 2026 |
| DIMENSIONAL FUND ADVISORS LP | 624,170 | 1.1M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 543,146 | 917.9K $ | as of Mar 31, 2026 |
| UBS Group AG | 537,569 | 908.5K $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 518,642 | 876.5K $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 374,812 | 633.4K $ | as of Mar 31, 2026 |
| HRT FINANCIAL LP | 286,444 | 484 $ | as of Mar 31, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 278,442 | 470.6K $ | as of Mar 31, 2026 |
| WOODSTOCK CORP | 266,756 | 450.8K $ | as of Mar 31, 2026 |
| IEQ CAPITAL, LLC | 266,518 | 450.4K $ | as of Mar 31, 2026 |
| CITADEL ADVISORS LLC | 266,340 | 450.1K $ | as of Mar 31, 2026 |
Declared shareholders of Aldeyra Therapeutics Inc
There is 1 beneficial ownership filing. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Perceptive Advisors LLC and 2 others | 0.00 % | 0 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of Aldeyra Therapeutics Inc". https://titelia.com/en/stocks/aldeyra-therapeutics-inc-US01438T1060